ClinicalTrials.gg
CompletedNCT04030598Updated Apr 3, 2023Results posted

A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema

A Phase 2 interventional study of Donidalorsen and Placebo in Hereditary Angioedema, sponsored by Ionis Pharmaceuticals, Inc.. Completed at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-03.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 84 studies in Angioedemas, Hereditary with a site in United States — 12 open to participants now, 18 under way, 10 of them phase 3. Angioedemas, Hereditary · United States.

Enrollment
58th of 74
23 · median 57
Started
2020
with 1 other
Phase 2
16 of 84
1 open now
Registered
42nd of 84
by date
Lead sponsor
5 of 84
Ionis Pharmaceuticals, Inc.

Among the 84 studies in Angioedemas, Hereditary with a site in United States, this one is the 58th largest by enrollment of the 74 interventional ones that give a count, is one of 2 that started in 2020, is one of 16 in phase 2, and was the 42nd registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

12 of the 84 studies in Angioedemas, Hereditary with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Angioedemas, Hereditary with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the clinical efficacy, safety, and tolerability of donidalorsen in participants with hereditary angioedema (HAE) type 1 (HAE-1), HAE type 2 (HAE-2), or HAE with normal C1-inhibitor (C1-INH) and to evaluate the effect of donidalorsen on plasma prekallikrein (PKK) and other relevant biomarkers.

Read the detailed description

This was a randomized, double-blind, placebo-controlled study in 23 participants conducted concurrently in 2 parts (Part A and Part B); participants were allocated into Part A or Part B according to type of HAE (i.e., either HAE-1/HAE-2 in Part A or HAE-nC1-INH in Part B). Part A was randomized, double-blind, and placebo-controlled; and Part B was open-label. The length of participation in the study was approximately 8 months, which included an up to 8-week screening period, a 12-week treatment period, and a 13-week post-treatment period.

03

Conditions studied

  • Hereditary Angioedema

Keywords

  • IONIS PKK-LRx
  • Donidalorsen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of HAE-1/HAE-2 (for inclusion in Part A) or HAE-nC1-INH (for inclusion in Part B)
  • Participants must have experienced a minimum of 2 HAE attacks (assessed by the Angioedema Activity Score [AAS] and confirmed by the investigator) during the screening period
  • Access to, and the ability to use, ≥ 1 acute medication(s) to treat angioedema attacks

Exclusion criteria

Exclusion Criteria:

  • Anticipated use of short-term prophylaxis for angioedema attacks for a pre-planned procedure during the screening or study periods
  • Concurrent diagnosis of any other type of recurrent angioedema, including acquired or idiopathic angioedema
  • Known history of or positive test for (HIV), , or chronic
  • within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated
  • Treatment with another drug or biological agent within 1 month or 5 half-lives, whichever is longer, of screening
  • Exposure to any of the following medications:

    • Angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing medications with systemic absorption (such as oral or hormonal replacement therapy) within 4 weeks prior to screening
    • Chronic prophylaxis with Lanadelumab within 10 weeks prior to screening
    • Oligonucleotides (including small interfering ribonucleic acid [RNA]) within 4 months of screening (if single dose received) or within 12 months of screening (if multiple doses received)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
23 participants (actual)

Study arms

  • Placebo comparator
    Part A: Placebo

    Participants with hereditary angioedema type I/type II (HAE-1/HAE-2) received placebo subcutaneously (SC) every 4 weeks at Weeks 1, 5, 9, and 13.

    Drug: Placebo

  • Experimental
    Part A: Donidalorsen 80 mg

    Participants with HAE-1/HAE-2 received donidalorsen, 80 mg, SC, every 4 weeks at Weeks 1, 5, 9, and 13.

    Drug: Donidalorsen

  • Experimental
    Part B: Donidalorsen 80 mg

    Participants with hereditary angioedema with normal C1-inhibitor (HAE-nC1-INH) received donidalorsen, 80 mg, SC, every 4 weeks at Weeks 1, 5, 9, and 13.

    Drug: Donidalorsen

Interventions

  • Donidalorsen administered SC

    Also known as: ISIS 721744, IONIS-PKK-LRx

  • DrugPlacebo

    Placebo matching solution administered SC

06

What researchers measure

Primary outcomes

  1. Time-normalized Number of HAE Attacks (Per Month) From Week 1 to Week 17

    The Week 1 to end of on-treatment period HAE attack rate was calculated for each participant as number of HAE attacks occurring from Week 1 to 28 days after the last dose date divided by the number of days the participant contributed to the period multiplied by 28 days. An HAE attack was defined as an event with signs or symptoms consistent with an attack in at least 1 of the locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx).

    Time frame: Week 1 to Week 17

Secondary outcomes

  1. Time-normalized Number of Investigator-confirmed HAE Attacks (Per Month) From Week 5 to Week 17

    The Week 5 to end of on-treatment period HAE attack rate was calculated for each participant as number of HAE attacks occurring from Week 5 to 28 days after the last dose date divided by the number of days the participant contributed to the period multiplied by 28 days. An HAE attack was defined as an event with signs or symptoms consistent with an attack in at least 1 of the locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx).

    Time frame: Week 5 to Week 17

  2. Time-normalized Number of Moderate or Severe Investigator-confirmed HAE Attacks (Per Month) From Week 5 to Week 17

    The Week 5 to end of on-treatment period HAE attack rate was calculated for each participant as number of moderate or severe HAE attacks occurring from Week 5 to 28 days after the last dose date divided by the number of days the participant contributed to the period multiplied by 28 days. An HAE attack was defined as an event with signs or symptoms consistent with an attack in at least 1 of the locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx). HAE attack severity: Mild: transient or mild discomfort, Moderate: mild to moderate limitation in activity, some assistance needed, and Severe: marked limitation in activity, assistance required.

    Time frame: Week 5 to Week 17

  3. Number of Participants With Clinical Response by Week 17

    Clinical response was defined as a ≥ 50%, ≥ 70%, or ≥ 90% reduction from Baseline in HAE attack rate from Week 5 to Week 17. The HAE attack rate was calculated as number of investigator-confirmed HAE attacks occurring from Week 5 to 28 days after last dose administration, divided by the number of days the participant contributed to the period multiplied by 28 days. An HAE attack was defined as an event with signs or symptoms consistent with an attack in at least 1 of the locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx).

    Time frame: Week 5 to Week 17

  4. Number of Investigator-confirmed HAE Attacks Requiring Acute Therapy From Week 5 to Week 17

    The Week 5 to end of on-treatment period HAE attack rate was calculated for each participant as number of HAE attacks requiring acute therapy occurring from Week 5 to 28 days after the last dose date divided by the number of days the participant contributed to the period multiplied by 28 days. An HAE attack was defined as an event with signs or symptoms consistent with an attack in at least 1 of the locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx). HAE attacks requiring acute therapy included those attacks with medical intervention or hospitalization marked on the case report form (CRFs).

    Time frame: Week 5 to Week 17

  5. Percentage of Cleaved High Molecular Weight Kininogen (cHMWK) Levels at Weeks 9 and 17

    High-molecular-weight kininogen (HMWK) is an abundant protein found in plasma and it has a critical role in acute attacks of HAE. During HAE attack plasma kallikrein cleaves HMWK producing cleaved HMWK (cHMWK) and bradykinin, the major biologic peptide that promotes the edema, one of the characteristic traits of HAE. Percentage of cHMWK levels were assessed to evaluate pharmacodynamics of donidalorsen.

    Time frame: Weeks 9 and 17

  6. Prekallikrein (PKK) Activity Levels at Weeks 9 and 17

    Prekallikrein (PKK) has a critical role in acute attacks of HAE. During HAE attack PKK is activated to form plasma kallikrein. Plasma kallikrein cleaves HMWK producing cleaved HMWK (cHMWK) and bradykinin, the major biologic peptide that promotes the edema, one of the characteristic traits of HAE. Prekallikrein levels were measured to assess pharmacodynamics of donidalorsen.

    Time frame: Weeks 9 and 17

  7. Number of Participants Who Consumed On-demand Medication at Weeks 9 and 17

    Treatment options for HAE included on-demand treatment of attacks and prophylaxis. On-demand medication options included supplementation of C1-INH (either plasma-derived or recombinant C1-INH concentrate) and inhibition of BK2 receptor activation (BK2-receptor antagonist). The number of participants who used on-demand medication at Week 9 (Day 57) and at Week 17 (end of the on-treatment period) were reported.

    Time frame: Weeks 9 and 17

  8. Change From Baseline in Angioedema Quality of Life (AE-QoL) Questionnaire Total Score at Weeks 9 and 17

    The AE-QoL was developed to measure health-related quality of life (HRQoL) impairment in participants with recurrent angioedema. The AE-QoL is a self-administered questionnaire that can be completed in less than 5 minutes. It comprises 17 items across 4 domains: functioning, fatigue/mood, fears/shame, and food. Responses use a 5-point Likert scale ranging from '0 = never' to '4 = very often.' Per-participant scores for each domain were computed using the appropriate scoring algorithm applied to the question response scores for each domain. Per-participant total scores (including all 4 domains) were similarly computed using the question response scores for all 17 questions. The outputs from the scoring algorithm were normalized on a scale ranging from 0 (less adverse impact) to 100 (most adverse impact). Global total score ranges from 0 to 100, with higher scores indicating greater impairment. Mixed model for repeated measures (MMRM) was used for analyses.

    Time frame: Baseline, Weeks 9 and 17

07

Results

Posted Sep 28, 2022

Participant flow

Participants took part in the study at 7 investigative sites from 7 January 2020 to 1 March 2021.

Participant flow — Overall Study
MilestonePart A: PlaceboPart A: Donidalorsen 80 mgPart B: Donidalorsen 80 mg
Started6143
Completed6133
Not completed010
Withdrew: Voluntary withdrawal010

Outcome measures

PrimaryTime-normalized Number of HAE Attacks (Per Month) From Week 1 to Week 17

The Week 1 to end of on-treatment period HAE attack rate was calculated for each participant as number of HAE attacks occurring from Week 1 to 28 days after the last dose date divided by the number of days the participant contributed to the period multiplied by 28 days. An HAE attack was defined as an event with signs or symptoms consistent with an attack in at least 1 of the locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx).

Time frame:
Week 1 to Week 17
Reported as:
Mean · HAE attacks per month
Time-normalized Number of HAE Attacks (Per Month) From Week 1 to Week 17
HAE attacks per monthPart A: PlaceboPart A: Donidalorsen 80 mgPart B: Donidalorsen 80 mg
Time-normalized Number of HAE Attacks (Per Month) From Week 1 to Week 172.21 ± 1.5580.23 ± 0.2681.52 ± 2.221
Statistical analysis
  • Part A: Placebo vs Part A: Donidalorsen 80 mg · Wald Chi-Square · p = 0.001 · Percentage difference: -90.00 · 95% CI -96.00 to -76.00The percentage difference in mean investigator-confirmed HAE attack rate between donidalorsen 80 mg and placebo was calculated as 100 percentage (%) × (mean rate ratio -1).
SecondaryTime-normalized Number of Investigator-confirmed HAE Attacks (Per Month) From Week 5 to Week 17

The Week 5 to end of on-treatment period HAE attack rate was calculated for each participant as number of HAE attacks occurring from Week 5 to 28 days after the last dose date divided by the number of days the participant contributed to the period multiplied by 28 days. An HAE attack was defined as an event with signs or symptoms consistent with an attack in at least 1 of the locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx).

Time frame:
Week 5 to Week 17
Reported as:
Mean · HAE attacks per month
Time-normalized Number of Investigator-confirmed HAE Attacks (Per Month) From Week 5 to Week 17
HAE attacks per monthPart A: PlaceboPart A: Donidalorsen 80 mgPart B: Donidalorsen 80 mg
Time-normalized Number of Investigator-confirmed HAE Attacks (Per Month) From Week 5 to Week 172.06 ± 1.5740.07 ± 0.2671.78 ± 2.795
Statistical analysis
  • Part A: Placebo vs Part A: Donidalorsen 80 mg · Wald Chi-Square · p = 0.003 · Percentage difference: -89.00 · 95% CI -95.00 to -77.00The percentage difference in mean investigator-confirmed HAE attack rate between donidalorsen 80 mg and placebo was calculated as 100% × (mean rate ratio -1).
SecondaryTime-normalized Number of Moderate or Severe Investigator-confirmed HAE Attacks (Per Month) From Week 5 to Week 17

The Week 5 to end of on-treatment period HAE attack rate was calculated for each participant as number of moderate or severe HAE attacks occurring from Week 5 to 28 days after the last dose date divided by the number of days the participant contributed to the period multiplied by 28 days. An HAE attack was defined as an event with signs or symptoms consistent with an attack in at least 1 of the locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx). HAE attack severity: Mild: transient or mild discomfort, Moderate: mild to moderate limitation in activity, some assistance needed, and Severe: marked limitation in activity, assistance required.

Time frame:
Week 5 to Week 17
Reported as:
Mean · HAE attacks per month
Time-normalized Number of Moderate or Severe Investigator-confirmed HAE Attacks (Per Month) From Week 5 to Week 17
HAE attacks per monthPart A: PlaceboPart A: Donidalorsen 80 mgPart B: Donidalorsen 80 mg
Time-normalized Number of Moderate or Severe Investigator-confirmed HAE Attacks (Per Month) From Week 5 to Week 171.25 ± 1.2080.05 ± 0.1780.89 ± 1.540
Statistical analysis
  • Part A: Placebo vs Part A: Donidalorsen 80 mg · Wald Chi-Square · p = 0.004 · Percentage difference: -96.00 · 95% CI -100.00 to -65.00The percentage difference in mean investigator-confirmed HAE attack rate between donidalorsen 80 mg and placebo was calculated as 100% × (mean rate ratio -1).
SecondaryNumber of Participants With Clinical Response by Week 17

Clinical response was defined as a ≥ 50%, ≥ 70%, or ≥ 90% reduction from Baseline in HAE attack rate from Week 5 to Week 17. The HAE attack rate was calculated as number of investigator-confirmed HAE attacks occurring from Week 5 to 28 days after last dose administration, divided by the number of days the participant contributed to the period multiplied by 28 days. An HAE attack was defined as an event with signs or symptoms consistent with an attack in at least 1 of the locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx).

Time frame:
Week 5 to Week 17
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response by Week 17
ParticipantsPart A: PlaceboPart A: Donidalorsen 80 mgPart B: Donidalorsen 80 mg
≥ 50% Reduction2132
≥ 70% Reduction1122
≥ 90% Reduction0121
Statistical analysis
  • Part A: Placebo vs Part A: Donidalorsen 80 mg · Fisher Exact · p = 0.004 · Risk difference (rd): 66.7 · 95% CI 17.5 to 95.7
  • Part A: Placebo vs Part A: Donidalorsen 80 mg · Fisher Exact · p = 0.003 · Risk difference (rd): 75.6 · 95% CI 26.8 to 96.5
  • Part A: Placebo vs Part A: Donidalorsen 80 mg · Fisher Exact · p = <0.001 · Risk difference (rd): 92.3 · 95% CI 48.0 to 99.8
SecondaryNumber of Investigator-confirmed HAE Attacks Requiring Acute Therapy From Week 5 to Week 17

The Week 5 to end of on-treatment period HAE attack rate was calculated for each participant as number of HAE attacks requiring acute therapy occurring from Week 5 to 28 days after the last dose date divided by the number of days the participant contributed to the period multiplied by 28 days. An HAE attack was defined as an event with signs or symptoms consistent with an attack in at least 1 of the locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx). HAE attacks requiring acute therapy included those attacks with medical intervention or hospitalization marked on the case report form (CRFs).

Time frame:
Week 5 to Week 17
Reported as:
Mean · HAE attacks per month
Number of Investigator-confirmed HAE Attacks Requiring Acute Therapy From Week 5 to Week 17
HAE attacks per monthPart A: PlaceboPart A: Donidalorsen 80 mgPart B: Donidalorsen 80 mg
Number of Investigator-confirmed HAE Attacks Requiring Acute Therapy From Week 5 to Week 171.25 ± 1.2080.05 ± 0.1780.89 ± 1.540
Statistical analysis
  • Part A: Placebo vs Part A: Donidalorsen 80 mg · Wald Chi-Square · p = 0.009 · Percentage difference: -95.00 · 95% CI -99.00 to -52.00
SecondaryPercentage of Cleaved High Molecular Weight Kininogen (cHMWK) Levels at Weeks 9 and 17

High-molecular-weight kininogen (HMWK) is an abundant protein found in plasma and it has a critical role in acute attacks of HAE. During HAE attack plasma kallikrein cleaves HMWK producing cleaved HMWK (cHMWK) and bradykinin, the major biologic peptide that promotes the edema, one of the characteristic traits of HAE. Percentage of cHMWK levels were assessed to evaluate pharmacodynamics of donidalorsen.

Time frame:
Weeks 9 and 17
Reported as:
Mean · percentage of cHMWK levels
Percentage of Cleaved High Molecular Weight Kininogen (cHMWK) Levels at Weeks 9 and 17
percentage of cHMWK levelsPart A: PlaceboPart A: Donidalorsen 80 mgPart B: Donidalorsen 80 mg
Week 95.62 ± 3.2552.07 ± 1.2411.03 ± 0.115
Week 177.00 ± 4.3382.35 ± 1.3532.13 ± 0.929
SecondaryPrekallikrein (PKK) Activity Levels at Weeks 9 and 17

Prekallikrein (PKK) has a critical role in acute attacks of HAE. During HAE attack PKK is activated to form plasma kallikrein. Plasma kallikrein cleaves HMWK producing cleaved HMWK (cHMWK) and bradykinin, the major biologic peptide that promotes the edema, one of the characteristic traits of HAE. Prekallikrein levels were measured to assess pharmacodynamics of donidalorsen.

Time frame:
Weeks 9 and 17
Reported as:
Mean · milligram per liter (mg/L)
Prekallikrein (PKK) Activity Levels at Weeks 9 and 17
milligram per liter (mg/L)Part A: PlaceboPart A: Donidalorsen 80 mgPart B: Donidalorsen 80 mg
Week 995.467 ± 23.719337.676 ± 14.563925.630 ± 19.2671
Week 1798.600 ± 34.594437.795 ± 38.661828.615 ± 22.8042
SecondaryNumber of Participants Who Consumed On-demand Medication at Weeks 9 and 17

Treatment options for HAE included on-demand treatment of attacks and prophylaxis. On-demand medication options included supplementation of C1-INH (either plasma-derived or recombinant C1-INH concentrate) and inhibition of BK2 receptor activation (BK2-receptor antagonist). The number of participants who used on-demand medication at Week 9 (Day 57) and at Week 17 (end of the on-treatment period) were reported.

Time frame:
Weeks 9 and 17
Reported as:
Count of participants · Participants
Number of Participants Who Consumed On-demand Medication at Weeks 9 and 17
ParticipantsPart A: PlaceboPart A: Donidalorsen 80 mgPart B: Donidalorsen 80 mg
Week 96123
Week 176113
Statistical analysis
  • Part A: Placebo vs Part A: Donidalorsen 80 mg · Fisher Exact · p = 1.000 · Risk difference (rd): -14.3 · 95% CI -59.1 to 33.9
  • Part A: Placebo vs Part A: Donidalorsen 80 mg · Fisher Exact · p = 0.521 · Risk difference (rd): -21.4 · 95% CI -64.9 to 27.1
SecondaryChange From Baseline in Angioedema Quality of Life (AE-QoL) Questionnaire Total Score at Weeks 9 and 17

The AE-QoL was developed to measure health-related quality of life (HRQoL) impairment in participants with recurrent angioedema. The AE-QoL is a self-administered questionnaire that can be completed in less than 5 minutes. It comprises 17 items across 4 domains: functioning, fatigue/mood, fears/shame, and food. Responses use a 5-point Likert scale ranging from '0 = never' to '4 = very often.' Per-participant scores for each domain were computed using the appropriate scoring algorithm applied to the question response scores for each domain. Per-participant total scores (including all 4 domains) were similarly computed using the question response scores for all 17 questions. The outputs from the scoring algorithm were normalized on a scale ranging from 0 (less adverse impact) to 100 (most adverse impact). Global total score ranges from 0 to 100, with higher scores indicating greater impairment. Mixed model for repeated measures (MMRM) was used for analyses.

Time frame:
Baseline, Weeks 9 and 17
Reported as:
Least squares mean · score on a scale
Change From Baseline in Angioedema Quality of Life (AE-QoL) Questionnaire Total Score at Weeks 9 and 17
score on a scalePart A: PlaceboPart A: Donidalorsen 80 mgPart B: Donidalorsen 80 mg
Change from Baseline at Week 9-1.50 ± 4.413-27.42 ± 2.85425.49 ± 17.421
Change from Baseline at Week 17-6.15 ± 4.671-26.85 ± 3.13326.96 ± 20.918
Statistical analysis
  • Part A: Placebo vs Part A: Donidalorsen 80 mg · Treatment difference: -25.92 · 95% CI -37.10 to -14.74
  • Part A: Placebo vs Part A: Donidalorsen 80 mg · Treatment difference: -20.69 · 95% CI -32.70 to -8.68

Adverse events

Collected over From first dose of study drug up to end of the study (Up to Week 26). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Placebo0/6 (0%)0/6 (0%)3/6 (50%)
Part A: Donidalorsen 80 mg0/14 (0%)0/14 (0%)2/14 (14.3%)
Part B: Donidalorsen 80 mg0/3 (0%)0/3 (0%)3/3 (100%)
Most frequent other events
Most frequent other events
EventPart A: PlaceboPart A: Donidalorsen 80 mgPart B: Donidalorsen 80 mg
VomitingGastrointestinal disorders0/60/141/3
HeadacheNervous system disorders2/62/140/3
Application site rashGeneral disorders0/60/141/3
Feeling hotGeneral disorders0/60/141/3
HyperhidrosisGeneral disorders0/60/141/3
NauseaGastrointestinal disorders1/61/140/3

Baseline characteristics

The safety population included all enrolled participants who received at least 1 dose of study drug (donidalorsen or placebo).

Age, Continuous
Age, Continuous(years)Part A: PlaceboPart A: Donidalorsen 80 mgPart B: Donidalorsen 80 mgTotal
Mean40.0 (22 to 56)37.8 (21 to 66)34.0 (25 to 40)37.26 (21 to 66)
Sex: Female, Male
Sex: Female, Male(Participants)Part A: PlaceboPart A: Donidalorsen 80 mgPart B: Donidalorsen 80 mgTotal
Female49316
Male2507
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: PlaceboPart A: Donidalorsen 80 mgPart B: Donidalorsen 80 mgTotal
Hispanic or Latino0101
Not Hispanic or Latino613322
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: PlaceboPart A: Donidalorsen 80 mgPart B: Donidalorsen 80 mgTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White514322
More than one race0000
Unknown or Not Reported0000
08

Study locations

8 sites
  • Medical Research of Arizona
    Scottsdale, Arizona 85251, United States
  • University of California San Diego (UCSD)
    San Diego, California 92122, United States
  • AIRE Medical of Los Angeles
    Santa Monica, California 90404, United States
  • Midwest Immunology Clinical
    Plymouth, Minnesota 55446, United States
  • Bernstein Clinical Research Center, LLC
    Cincinnati, Ohio 45231, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • AARA Research Center
    Dallas, Texas 75231, United States
  • Amsterdam UMC, loc. AMC
    Amsterdam, 1105 AZ, Netherlands
09

References and documents

Publications

  • Fijen LM, Riedl MA, Bordone L, Bernstein JA, Raasch J, Tachdjian R, Craig T, Lumry WR, Manning ME, Alexander VJ, Newman KB, Revenko A, Baker BF, Nanavati C, MacLeod AR, Schneider E, Cohn DM. Inhibition of Prekallikrein for Hereditary Angioedema. N Engl J Med. 2022 Mar 17;386(11):1026-1033. doi: 10.1056/NEJMoa2109329. PubMed 35294812 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Jan 2021, 11 months.

Results were first posted in Sep 2022, 1 year 8 months after primary completion.

Of 17 phase 2 interventional studies under Angioedemas, Hereditary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2019
First posted
Jul 24, 2019
StartActual
Jan 7, 2020
Primary completionActual
Jan 4, 2021
CompletionActual
Mar 1, 2021
Results first posted
Sep 28, 2022
Last update
Apr 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04030598
Responsible party
Sponsor
First posted
Jul 24, 2019
Start date
Jan 7, 2020
Primary completion
Jan 4, 2021
Completion
Mar 1, 2021
Results posted
Sep 28, 2022
Last update
Apr 3, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donidalorsen

Start the discussion